Home/Filings/4/0001062993-22-007530
4//SEC Filing

Montecalvo Antonio S. 4

Accession 0001062993-22-007530

CIK 0001661181other

Filed

Mar 10, 7:00 PM ET

Accepted

Mar 11, 6:42 PM ET

Size

14.0 KB

Accession

0001062993-22-007530

Insider Transaction Report

Form 4
Period: 2022-03-09
Montecalvo Antonio S.
Vice President, Health Policy
Transactions
  • Exercise/Conversion

    Class A Common Stock

    2022-03-10$3.46/sh+46,103$159,516119,324 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2022-03-1046,10355,397 total
    Exercise: $3.46Exp: 2027-05-04Class A Common Stock (46,103 underlying)
  • Exercise/Conversion

    Class A Common Stock

    2022-03-10$3.46/sh+22,401$77,507141,725 total
  • Sale

    Class A Common Stock

    2022-03-09$8.52/sh10,000$85,20073,221 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2022-03-1022,40178,175 total
    Exercise: $3.46Exp: 2027-05-04Class A Common Stock (22,401 underlying)
  • Sale

    Class A Common Stock

    2022-03-10$8.39/sh97,436$817,48844,289 total
Footnotes (4)
  • [F1]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.54, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
  • [F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $8.34 to $8.42, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
  • [F3]The shares underlying the option vested or shall vest 20% annually beginning on January 1, 2018.
  • [F4]The shares underlying the option vested or shall vest 20% annually beginning on December 31, 2017.

Issuer

Organogenesis Holdings Inc.

CIK 0001661181

Entity typeother

Related Parties

1
  • filerCIK 0001759261

Filing Metadata

Form type
4
Filed
Mar 10, 7:00 PM ET
Accepted
Mar 11, 6:42 PM ET
Size
14.0 KB